High Prediagnosis Inflammation-Related Risk Score Associated with Decreased Ovarian Cancer Survival

Details

• Personal Author:
  Anton-Culver H ; Bakulski KM ; Bandera EV ; Berchuck A ; Bowtell DDL ; Brenton JD ; Brieger KK ; Chase A ; Cho KR ; Cramer DW ; DeFazio A ; Deurloo CM ; Doherty JA ; Fereday S ; Fortner RT ; Gentry-Maharaj A ; Goode EL ; Goodman MT ; Grout B ; Hanley GE ; Harris HR ; Khoja L ; Matsuo K ; McLean K ; Menon U ; Modugno F ; Moysich KB ; Mukherjee B ; Nelson BH ; Odunsi K ; Pearce CL ; Pharoah PDP ; Phung MT ; Pike MC ; Qin B ; Ramus SJ ; Richardson J ; Risch HA ; Rossing MA ; Schildkraut JM ; Terry KL ; Trabert B ; Vierkant RA ; Webb PM ; Wentzensen N ; Winham SJ ; Wu AH ; Ziogas A
• Corporate Authors:
  Ovarian Cancer Association Consortium
• Description:
  Background: There is suggestive evidence that inflammation is related to ovarian cancer survival. However, more research is needed to identify inflammation-related factors that are associated with ovarian cancer survival and to determine their combined effects. Methods: This analysis used pooled data on 8,147 women with invasive epithelial ovarian cancer from the Ovarian Cancer Association Consortium. The prediagnosis inflammation-related exposures of interest included alcohol use; aspirin use; other nonsteroidal anti-inflammatory drug use; body mass index; environmental tobacco smoke exposure; history of pelvic inflammatory disease, polycystic ovarian syndrome, and endometriosis; menopausal hormone therapy use; physical inactivity; smoking status; and talc use. Using Cox proportional hazards models, the relationship between each exposure and survival was assessed in 50% of the data. A weighted inflammation-related risk score (IRRS) was developed, and its association with survival was assessed using Cox proportional hazards models in the remaining 50% of the data. Results: There was a statistically significant trend of increasing risk of death per quartile of the IRRS [HR = 1.09; 95% confidence interval (CI), 1.03-1.14]. Women in the upper quartile of the IRRS had a 31% higher death rate compared with the lowest quartile (95% CI, 1.11-1.54). Conclusions: A higher prediagnosis IRRS was associated with an increased mortality risk after an ovarian cancer diagnosis. Further investigation is warranted to evaluate whether postdiagnosis exposures are also associated with survival. Impact: Given that pre- and postdiagnosis exposures are often correlated and many are modifiable, our study results can ultimately motivate the development of behavioral recommendations to enhance survival among patients with ovarian cancer. [Description provided by NIOSH]
• Subjects:
  Epidemiology Immune System Mortality Neoplasms Occupational Health Safety
• Keywords:
  Cancer Rates Chronic Inflammation DNA Damage Immune Reaction Mortality Rates Ovarian Cancer
• ISSN:
  1055-9965
• Document Type:
  Text
• Funding:
  Grant
• Genre:
  Journal Article
• Place as Subject:
  California ; Connecticut ; Georgia ; Maryland ; Massachusetts ; Michigan ; Minnesota ; New Jersey ; New York ; OSHA Region 1 ; OSHA Region 10 ; OSHA Region 2 ; OSHA Region 3 ; OSHA Region 4 ; OSHA Region 5 ; OSHA Region 8 ; OSHA Region 9 ; Pennsylvania ; Utah ; Washington
• CIO:
  National Institute for Occupational Safety and Health (NIOSH)
• Topic:
  Workplace Safety & Health
• Location:
  North America
• Pages in Document:
  443-452
• Volume:
  31
• Issue:
  2
• NIOSHTIC Number:
  nn:20070643
• Citation:
  Cancer Epidemiol Biomark Prev 2022 Feb; 31(2):443-452
• Contact Point Address:
  Celeste Leigh Pearce, Department of Epidemiology, University of Michigan School of Public Health, 1415 Washington Heights, Ann Arbor, Michigan 48109-2029
• Email:
  lpearce@umich.edu
• Federal Fiscal Year:
  2022
• Performing Organization:
  University of Michigan, Ann Arbor
• Peer Reviewed:
  True
• Start Date:
  20050701
• Source Full Name:
  Cancer Epidemiology, Biomarkers & Prevention
• End Date:
  20280630
• Collection(s):
  National Institute for Occupational Safety and Health
• Main Document Checksum:
  urn:sha-512:264232ff112694c439420b8079bbafdac7a11e225a8527cd599b552e8ccf3a7fefc2a52276192c971fb7a6b33de77c15a65df6c575faf8cf59cb2ee421faa88d
• Download URL:
  https://stacks.cdc.gov/view/cdc/208822/cdc_208822_DS1.pdf
• File Type:
  [PDF - 268.37 KB ]